International Investment and Indigenous Peoples' Environment: A Survey of ISDS Cases from 2000 to 2020.

Int J Environ Res Public Health

Guanghua Law School, Zhejiang University, Hangzhou 310008, China.

Published: July 2021

Indigenous peoples' environments can be easily disrupted by foreign investments, and disputes have occasionally occurred over the past few years. The objective of this research article is to examine if current international investment law, especially its investor-state dispute settlement (ISDS) mechanism, could provide necessary protection to Indigenous rights. We searched all publicly available ISDS cases from 2000 to 2020, and selected 10 typical ones for comprehensive case study by using various research methods such as doctrinal legal research and comparative analysis. Our research revealed that Indigenous peoples' participation in the ISDS proceedings is legally restrained, time-consuming, and rarely favorably decided by the arbitral tribunals. Responsibility for such undesirable outcomes rests with all stakeholders involved in the process, while the consequences of post-arbitration tend to be "triple losing". These findings highlight the quest for a more sustainable international investment regime that promotes Indigenous peoples' wellbeing and environment protection. We argue that future reform could be promoted not only over ISDS procedural matters, but also by upgrading substantive rules in international investment agreements (IIAs), emphasizing free, prior, and informed consent (FPIC), and strengthening foreign investors' corporate social responsibilities (CSR).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345368PMC
http://dx.doi.org/10.3390/ijerph18157798DOI Listing

Publication Analysis

Top Keywords

international investment
16
indigenous peoples'
16
isds cases
8
cases 2000
8
2000 2020
8
indigenous
5
isds
5
international
4
investment indigenous
4
peoples'
4

Similar Publications

Rationale: Early detection, standardized therapy, adequate infrastructure and strategies for quality improvement should constitute essential components of every hospital's sepsis plan.

Objectives: To investigate the extent to which recommendations from the sepsis guidelines are implemented and the availability of infrastructure for the care of patients with sepsis in acute hospitals.

Methods: A multidisciplinary cross-sectional questionnaire was used to investigate sepsis care in hospitals.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Memory and Aging Center, UCSF Weill Institute for Neurosciences, San Francisco, CA, USA.

Background: Collection, storage, and distribution of human fluid biospecimens in a scientifically rigorous manner is challenging. It requires physical space availability and robust infrastructure. Nonetheless, it is key to contribute to research in Alzheimer's Disease and Related Disorders, including Frontotemporal Dementia (FTD).

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

PCORI, Washington, DC, USA.

Background: National and international organizations, including the United Nations, Center for Disease Control, Agency for Healthcare Research and Quality, and the US Surgeon General's Office have highlighted the need for a comprehensive approach to caring for the growing number of older adults in the U.S. Furthermore, advancements in both non-pharmacological and pharmacological treatments for Alzheimer's Disease and Related Dementias (ADRD), coupled with the CMS initiative on improving dementia care management (GUIDE), have intensified national attention on the needs of older adults living with ADRD.

View Article and Find Full Text PDF

Disease foci of pharmaceutical research and development as reflected in applications for International Nonproprietary Names, 1953-2022.

Bull World Health Organ

January 2025

INN Programme and Classification of Medical Products, World Health Organization, 20 Avenue Appia, 1211Geneva, Switzerland.

Objective: To evaluate trends in pharmaceutical research and development, and to correlate these trends with global medical need.

Methods: We obtained details of proposed pharmaceutical substances from 1953 to 2022 from the International Nonproprietary Names (INN) database. We used the DrugBank and Cortellis databases to obtain the INN included in approved medicines over the same period.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!